In vivo studies in rodents treated with SGLT2 inhibitors have also been promising, if limited: canagliflozin lowered tumor burden in mice with hepatocellular [44–46], lung [47], and renal cell carcinoma [43] in vivo. Here, SLC5A2 is linked to hereditary clear cell renal cell carcinoma.